Skip Navigation

Cardiovascular Research 2007 73(3):446-447; doi:10.1016/j.cardiores.2006.12.008
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Inserte, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inserte, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Triggering of cardiac preconditioning through Na+/K+-ATPase

Javier Inserte*

Servicio de Cardiologia, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron, 119-129, 08035 Barcelona, Spain

* Tel.: +34 93 4894038; fax: +34 93 4894032. Email address: jinserte{at}ir.vhebron.net

Received 5 December 2006; accepted 7 December 2006

See article by Pierre et al. [6] (pages 488–496) in this issue.

It has been two decades since the first reports describing the phenomenon of ischemic preconditioning (IP). Data generated during these years describe a wide range of pharmacological triggers of IP, different intracellular signalling pathways, and some end-effectors of the powerful protection that IP exerts against cell death [1].

One of the most recent mechanisms that has been proposed to explain the protection induced by IP involves Na+/K+-ATPase. It is well accepted that the kinetics of Na+ recovery during reperfusion determines the influx of Ca2+ through the reverse mode of the Na+/Ca2+-exchanger and, consequently, the degree of injury [2], and it has been consistently reported that IP accelerates Na+ kinetics during early reperfusion by preserving Na+/K+-ATPase activity [3]. Recently, it has been proposed that the cardioprotective effects of IP are at least in part mediated by attenuated calpain activation, resulting in decreased displacement of Na+/K+-ATPase from the membrane-cytoskeleton complex, preserved Na+ pump activity, and attenuated Ca2+ influx through NCX [4]. By contrast, inhibition of Na+/K+-ATPase with ouabain at the onset of reperfusion completely abolished the protective effects afforded by IP.

Recently, several groups have proposed that Na+/K+-ATPase has dual functions. In addition to pumping Na+ and K+ across cell membranes, it also relays an extracellular ouabain signal to intracellular compartments via activation of different protein kinases [5]. In this issue of Cardiovascular Research, Pierre et al. [6] add new evidence to the growing body of studies that support the existence of this signal-transducing function of Na+/K+-ATPase, and demonstrate that activation of this pathway by perfusion of isolated rat hearts with ouabain induces cardioprotection. Although, as the authors recognize, these results could apparently be in contradiction to the classical notion that preservation of Na+/K+-ATPase activity and its control of Na+ homeostasis is protective, an effect of ouabain on intracellular Na+ concentration in their study seems extremely unlikely: ouabain was given as a transient stimulus (for 4 min followed by washout) and the concentration used (10 µM) had negligible positive inotropic effects.

The author's group has made important contributions helping to unravel many of the mechanisms that underlie the function of Na+/K+-ATPase as a signal transducer. In earlier studies they demonstrated that tyrosine kinases of the Src family are involved in the ouabain activation of the signal-transducing function of Na+/K+-ATPase [7]. After observing that Na+/K+-ATPase interacts with caveolin-1 and that ouabain regulates this interaction and induces the formation of a Na+/K+-ATPase-Src-caveolin-1 signaling complex in a cell line, they proposed that signaling mediated by Na+/K+-ATPase resides in membrane microdomains such as caveolae [8]. Whether the same localization occurs in myocytes needs further investigation. The question whether Src interacts with Na+/K+-ATPase directly or indirectly has been recently resolved: SH2 and kinase domains of Src interact with CD2 and CD3 domains of alpha subunit of Na+/K+-ATPase. These interactions maintain Src in an inactive state, and binding of ouabain to the Na+/K+-ATPase-Src complex activates associated Src, which subsequently provokes downstream protein tyrosine phosphorylation [9].

The epidermal growth factor (EGF) receptor is one of the proteins identified as substrates of Src [10]. Its phosphorylation activates the signaling cascade Ras/Raf/ERK1/2 leading to stimulation of mitochondrial reactive oxygen species (ROS) generation and the activation of NF-{kappa}B. This pathway seems to be essential for the observed hypertrophic effects of ouabain on cardiomyocytes. Another substrate of Src is phospholipase C-{gamma}1 (PLC-{gamma}1), which activates the protein kinase C (PKC) pathway [11]. In their paper, Pierre et al. [6] demonstrate, by using pharmacological inhibitors, the involvement of activated Src and PKC{varepsilon} in the cardioprotective effects of transient perfusion with ouabain. Whether the EGF pathway also contributes to this preconditioning-like protection and what are the cardioprotective mediators and final effectors linked to the proposed signaling pathway were not addressed by this study. However, the involvement of PKC{varepsilon} connects this study with the conclusions of different groups that propose this enzyme as a critical mediator of IP. Cardiac-specific overexpression of PKC{varepsilon} has been shown to confer protection against reperfusion-induced injury [12], while IP fails to protect PKC{varepsilon} knockout mice [13]. The role of PKC{varepsilon} in IP has been recently reviewed by Inagaki et al. [14]. In their paper two proposed mechanisms, both associated with the mitochondria, are analyzed as possible effectors for explaining the cardioprotective effects of PKC{varepsilon}: opening of the KATP channel and inhibition of mitochondrial permeability transition pore opening during reperfusion.

In parallel to the study published in this issue, Pierre and co-authors have provided more evidence supporting the possibility that ouabain may be cardioprotective in the therapeutic dose range [15]. Continuous perfusion of isolated hearts with ouabain at concentrations without inotropic response before ischemia initiated a cardioprotective signaling pathway that induced ROS production and required mitochondrial KATP channel opening.

The observations by Pierre et al. open new perspectives in the study of the signal-transduction function of Na+/K+-ATPase by demonstrating that its transient activation has strong physiologically relevant consequences, such as induction of cardiac tolerance to ischemic stress, and point to the interest of developing drugs that stimulate the signaling function of the Na+/K+-ATPase without affecting its ion pumping activity. In summary, Pierre et al. [6] propose that the activation of the signaling function of Na+/K+-ATPase as a new cardioprotective stimulus should be added to the long list of described preconditioning triggers. The focus of research efforts should probably move from triggers to final effectors if we want to translate this powerful cardioprotective effect of IP into a clinically relevant setting.


   Acknowledgments
Top
 Acknowledgments
References
 
Partially supported by grants CICYT SAF 2005-01758 and FIS-RECAVA.


   References
Top
 Acknowledgments
 References
 

  1. Garcia-Dorado D., Rodriguez-Sinovas A., Ruiz-Meana M., Inserte J., Agullo L., Cabestrero A. The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia–reperfusion. Cardiovasc Res (2006) 70:274–285.[Abstract/Free Full Text]
  2. Inserte J., Garcia-Dorado D., Hernando V., Barba I., Soler-Soler J. Ischemic preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion. Cardiovasc Res (2006) 70:364–373.[Abstract/Free Full Text]
  3. Imahashi K., Nishimura T., Yoshioka J., Kusuoka H. Role of intracellular Na(+) kinetics in preconditioned rat heart. Circ Res (2001) 88:1176–1182.[Abstract/Free Full Text]
  4. Inserte J., Garcia-Dorado D., Hernando V., Soler-Soler J. Calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia. Circ Res (2005) 97:465–473.[Abstract/Free Full Text]
  5. Xie Z. Molecular mechanisms of Na/K-ATPase-mediated signal transduction. Ann NY Acad Sci (2003) 986:497–503.[Web of Science][Medline]
  6. Pierre S.V., Yang C., Yuan Z., Seminerio J., Mouas C., Garlid K.D., et al. Ouabain triggers preconditioning through activation of the Na+,K+-ATPase signaling cascade in rat hearts. Cardiovasc Res (2007) 73:488–496.[Abstract/Free Full Text]
  7. Haas M., Askari A., Xie Z. Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase. J Biol Chem (2000) 275:27832–27837.[Abstract/Free Full Text]
  8. Wang H., Haas M., Liang M., Cai T., Tian J., Li S., et al. Ouabain assembles signaling cascades through the caveolar Na+/K+-ATPase. J Biol Chem (2004) 279:17250–17259.[Abstract/Free Full Text]
  9. Tian J., Cai T., Yuan Z., Wang H., Liu L., Haas M., et al. Binding of Src to Na+/K+-ATPase forms a functional signaling complex. Mol Biol Cell (2006) 17:317–326.[Abstract/Free Full Text]
  10. Haas M., Askari A., Xie Z. Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase. J Biol Chem (2000) 275:27832–27837.[Abstract/Free Full Text]
  11. Yuan Z., Cai T., Tian J., Ivanov A.V., Giovannucci D.R., Xie Z. Na/K-ATPase tethers phospholipase C and IP3 receptor into a calcium-regulatory complex. Mol Biol Cell (2005) 16:4034–4045.[Abstract/Free Full Text]
  12. Ping P., Song C., Zhang J., Guo Y., Cao X., Li R.C., et al. Formation of protein kinase C(epsilon)-Lck signaling modules confers cardioprotection. J Clin Invest (2002) 109:499–507.[CrossRef][Web of Science][Medline]
  13. Saurin A.T., Pennington D.J., Raat N.J., Latchman D.S., Owen M.J., Marber M.S. Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse hearts. Cardiovasc Res (2002) 55:672–680.[Abstract/Free Full Text]
  14. Inagaki K., Churchill E., Mochly-Rosen D. Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc Res (2006) 70:222–230.[Abstract/Free Full Text]
  15. Pasdois P, Quinlan CL, Rissa A, Tariosse L, Vinassa B, Costa AD, et al. Ouabain protects rat hearts against ischemia–reperfusion injury via a pathway involving src kinase, mitoKATP, and ROS. Am J Physiol Heart Circ Physiol in press (November 10, 2006). doi:10.1152/ajpheart.00877.2006.

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Inserte, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inserte, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?